Total Payments
$16,236
2024 Payments
$579.89
Companies
41
Transactions
720
Medicare Patients
12,751
Medicare Billing
$2.8M
Payment Breakdown by Category
Food & Beverage$11,098 (68.4%)
Other$3,850 (23.7%)
Consulting$1,269 (7.8%)
Education$18.64 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $11,098 | 713 | 68.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3,850 | 3 | 23.7% |
| Consulting Fee | $1,269 | 1 | 7.8% |
| Education | $18.64 | 3 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $5,777 | 46 | $0 (2022) |
| Janssen Pharmaceuticals, Inc | $2,351 | 189 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $2,263 | 128 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $768.72 | 44 | $0 (2024) |
| Amgen Inc. | $753.87 | 58 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $631.93 | 48 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $484.71 | 25 | $0 (2023) |
| Gilead Sciences, Inc. | $438.82 | 41 | $0 (2019) |
| Boston Scientific Corporation | $264.67 | 9 | $0 (2023) |
| BIOTRONIK INC. | $250.67 | 2 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $579.89 | 34 | Novartis Pharmaceuticals Corporation ($157.65) |
| 2023 | $666.52 | 31 | Novartis Pharmaceuticals Corporation ($308.31) |
| 2022 | $1,304 | 76 | Novartis Pharmaceuticals Corporation ($350.48) |
| 2021 | $6,955 | 116 | AstraZeneca Pharmaceuticals LP ($5,349) |
| 2020 | $1,049 | 72 | Janssen Pharmaceuticals, Inc ($302.66) |
| 2019 | $1,701 | 119 | Janssen Pharmaceuticals, Inc ($447.19) |
| 2018 | $2,244 | 150 | Janssen Pharmaceuticals, Inc ($566.01) |
| 2017 | $1,738 | 122 | Novartis Pharmaceuticals Corporation ($460.98) |
All Payment Transactions
720 individual payment records from CMS Open Payments — Page 1 of 29
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/16/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $14.37 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 12/12/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $14.57 | General |
| Category: Cardiovascular | ||||||
| 12/11/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $14.78 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/08/2024 | Kiniksa Pharmaceuticals International, plc | Arcalyst (Drug) | Food and Beverage | In-kind items and services | $27.67 | General |
| Category: Not Applicable | ||||||
| 11/06/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $16.81 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/04/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $12.63 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/04/2024 | PFIZER INC. | ELIQUIS (Drug), NURTEC ODT, ZAVZPRET | Food and Beverage | In-kind items and services | $13.72 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 09/30/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $10.75 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/11/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $16.24 | General |
| Category: Cardiovascular | ||||||
| 09/09/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $12.35 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/05/2024 | PFIZER INC. | ELIQUIS (Drug), NURTEC ODT | Food and Beverage | In-kind items and services | $15.64 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 09/04/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $22.20 | General |
| Category: CARDIOVASCULAR | ||||||
| 08/14/2024 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $13.48 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 08/12/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $11.20 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 08/12/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $0.25 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 07/09/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $11.01 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 07/08/2024 | Lexicon Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $33.94 | General |
| 06/27/2024 | Kiniksa Pharmaceuticals International, plc | Arcalyst (Drug) | Food and Beverage | In-kind items and services | $21.78 | General |
| Category: Not Applicable | ||||||
| 06/20/2024 | SANOFI-AVENTIS U.S. LLC | MULTAQ (Drug) | Food and Beverage | In-kind items and services | $23.35 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 05/29/2024 | Lexicon Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $33.11 | General |
| 05/24/2024 | SANOFI-AVENTIS U.S. LLC | MULTAQ (Drug) | Food and Beverage | In-kind items and services | $19.01 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 05/23/2024 | VivaQuant Inc, dba Rhythm Express | Rhythm Express (Device) | Food and Beverage | Cash or cash equivalent | $21.84 | General |
| Category: Remote Cardiac Monitoring | ||||||
| 05/22/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $16.24 | General |
| Category: Cardiovascular | ||||||
| 05/15/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $14.86 | General |
| Category: Diabetes | ||||||
| 05/13/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $11.33 | General |
| Category: Cardiology/Vascular Diseases | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 26 | 2,702 | 4,346 | $1.6M | $639,319 |
| 2022 | 38 | 3,261 | 5,689 | $1.8M | $754,512 |
| 2021 | 39 | 3,215 | 5,503 | $1.4M | $644,210 |
| 2020 | 45 | 3,573 | 6,367 | $1.7M | $729,684 |
Total Patients
12,751
Total Services
21,905
Medicare Billing
$2.8M
Procedure Codes
151
All Medicare Procedures & Services
151 procedure records from CMS Medicare Utilization — Page 1 of 7
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 78431 | Nuclear medicine studies of blood flow in heart muscle at rest and with stress with concurrent ct scan | Office | 2023 | 166 | 166 | $664,000 | $303,801 | 45.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 515 | 1,086 | $152,040 | $85,077 | 56.0% |
| A9555 | Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | Office | 2023 | 169 | 338 | $126,750 | $76,277 | 60.2% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 305 | 310 | $263,500 | $41,177 | 15.6% |
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2023 | 174 | 696 | $52,200 | $29,547 | 56.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 152 | 234 | $42,120 | $27,739 | 65.9% |
| 93880 | Ultrasound of both sides of head and neck blood flow | Office | 2023 | 77 | 78 | $35,100 | $9,960 | 28.4% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 81 | 146 | $12,410 | $8,426 | 67.9% |
| 93015 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | Office | 2023 | 175 | 177 | $42,480 | $7,923 | 18.7% |
| 93458 | Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | Facility | 2023 | 36 | 37 | $43,364 | $6,608 | 15.2% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 44 | 48 | $10,320 | $6,032 | 58.5% |
| 92928 | Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | Facility | 2023 | 12 | 13 | $34,866 | $5,082 | 14.6% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 376 | 457 | $27,420 | $4,223 | 15.4% |
| 93925 | Ultrasound of leg arteries or artery grafts | Office | 2023 | 23 | 23 | $6,325 | $3,810 | 60.2% |
| 93280 | Programming of dual lead pacemaker system | Office | 2023 | 49 | 57 | $5,130 | $3,096 | 60.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 33 | 33 | $6,006 | $3,094 | 51.5% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 23 | 34 | $4,250 | $2,976 | 70.0% |
| 93970 | Ultrasound study of arm or leg veins with compression and maneuvers | Office | 2023 | 21 | 21 | $6,027 | $2,698 | 44.8% |
| 93224 | Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | Office | 2023 | 51 | 54 | $17,280 | $2,570 | 14.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 15 | 15 | $3,300 | $2,163 | 65.5% |
| 93923 | Complete ultrasound study of arm and leg arteries | Office | 2023 | 23 | 23 | $7,475 | $1,837 | 24.6% |
| 93294 | Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | Office | 2023 | 32 | 61 | $3,233 | $1,225 | 37.9% |
| 93296 | Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | Office | 2023 | 42 | 85 | $4,505 | $1,186 | 26.3% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 18 | 18 | $2,070 | $1,084 | 52.4% |
| 99152 | Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | Facility | 2023 | 41 | 84 | $6,450 | $766.58 | 11.9% |
About Dr. Michael Rihner, MD
Dr. Michael Rihner, MD is a Cardiovascular Disease healthcare provider based in Mobile, Alabama. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/16/2006. The National Provider Identifier (NPI) number assigned to this provider is 1831279702.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Rihner, MD has received a total of $16,236 in payments from pharmaceutical and medical device companies, with $579.89 received in 2024. These payments were reported across 720 transactions from 41 companies. The most common payment nature is "Food and Beverage" ($11,098).
As a Medicare-enrolled provider, Rihner has provided services to 12,751 Medicare beneficiaries, totaling 21,905 services with total Medicare billing of $2.8M. Data is available for 4 years (2020–2023), covering 151 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Mobile, AL
- Active Since 10/16/2006
- Last Updated 11/08/2010
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1831279702
Products in Payments
- BRILINTA (Drug) $5,656
- XARELTO (Drug) $2,351
- ENTRESTO (Drug) $1,910
- ELIQUIS (Drug) $686.00
- JARDIANCE (Drug) $472.98
- PRALUENT (Drug) $418.55
- Repatha (Biological) $373.67
- Corlanor (Drug) $366.20
- LEQVIO (Drug) $352.65
- MULTAQ (Drug) $350.17
- Orsiro Mission (Device) $250.67
- LifeVest (Device) $196.02
- LEXISCAN (Drug) $188.17
- Cardiac Monitoring Suite (Device) $173.38
- Vascepa (Drug) $166.94
- Edarbyclor (Drug) $147.26
- NORTHERA (Drug) $141.62
- WATCHMAN (Device) $119.60
- FARXIGA (Drug) $104.47
- PRALUENT ALIROCUMAB INJECTION (Biological) $85.77
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Mobile
Dr. Dennis Thomas, M.d, M.D
Cardiovascular Disease — Payments: $885,159
Cardiovascular Disease $885,159
Dr. Kenneth Burnham, Md, MD
Cardiovascular Disease — Payments: $471,311
Cardiovascular Disease $471,311
Jordan Chaisson, M.d, M.D
Cardiovascular Disease — Payments: $96,312
Cardiovascular Disease $96,312
Luanda Grazette, M.d, M.D
Cardiovascular Disease — Payments: $39,914
Cardiovascular Disease $39,914
J O'dowd, Md, MD
Cardiovascular Disease — Payments: $27,472
Cardiovascular Disease $27,472
Chance Witt, Md, MD
Cardiovascular Disease — Payments: $18,119
Cardiovascular Disease $18,119